$NEOV
NeoVolta Inc.

2024 Q2 Form 10-Q Financial Statement

#000168316824003236 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $579.2K $283.9K
YoY Change -19.55% -54.87%
Cost Of Revenue $562.1K $117.8K
YoY Change 19.59% -78.08%
Gross Profit $17.15K $166.1K
YoY Change -93.4% 81.09%
Gross Profit Margin 2.96% 58.52%
Selling, General & Admin $742.2K $756.1K
YoY Change 27.96% 4.54%
% of Gross Profit 4327.52% 455.1%
Research & Development $8.760K $10.39K
YoY Change 705.58%
% of Gross Profit 51.08% 6.25%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $750.9K $766.5K
YoY Change 31.74% 5.79%
Operating Profit -$733.8K -$600.4K
YoY Change 136.7% -5.13%
Interest Expense $4.700K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $10.89K
YoY Change
Pretax Income -$729.1K -$589.5K
YoY Change 127.84% -6.85%
Income Tax
% Of Pretax Income
Net Earnings -$729.1K -$589.5K
YoY Change 127.84% -6.85%
Net Earnings / Revenue -125.87% -207.63%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$0.02 -$0.02
COMMON SHARES
Basic Shares Outstanding 33.24M shares 33.24M shares
Diluted Shares Outstanding 33.24M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $986.4K $1.014M
YoY Change -50.68% -70.7%
Cash & Equivalents $986.4K $1.014M
Short-Term Investments
Other Short-Term Assets $76.82K $115.2K
YoY Change -23.18% -43.99%
Inventory $1.787M $2.137M
Prepaid Expenses
Receivables $1.806M $1.887M
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.657M $5.153M
YoY Change -28.43% -23.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $4.657M $5.153M
Total Long-Term Assets $0.00 $0.00
Total Assets $4.657M $5.153M
YoY Change -28.43% -23.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.316K $3.167K
YoY Change
Accrued Expenses $55.78K $11.88K
YoY Change 39.45% -86.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.10K $15.05K
YoY Change 54.72% -82.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $61.10K $15.05K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $61.10K $15.05K
YoY Change 54.72% -82.83%
SHAREHOLDERS EQUITY
Retained Earnings -$20.74M -$20.01M
YoY Change 12.49% 10.46%
Common Stock $33.24K $33.24K
YoY Change 0.24% 0.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.595M $5.138M
YoY Change
Total Liabilities & Shareholders Equity $4.657M $5.153M
YoY Change -28.43% -23.84%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$729.1K -$589.5K
YoY Change 127.84% -6.85%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$27.53K -$485.3K
YoY Change -98.11% -1394.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -27.53K -485.3K
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000
Net Change In Cash -27.53K -485.3K
YoY Change -98.11% -1394.56%
FREE CASH FLOW
Cash From Operating Activities -$27.53K -$485.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33236091 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33236091 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33155127 shares
CY2024Q1 us-gaap Interest Expense
InterestExpense
-0 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
-0 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33236091 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33151685 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33151685 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2065858 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2733951 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1572668 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2302380 usd
us-gaap Gross Profit
GrossProfit
493190 usd
us-gaap Gross Profit
GrossProfit
431571 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2085976 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2716428 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10392 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29936 usd
us-gaap Operating Expenses
OperatingExpenses
2096368 usd
us-gaap Operating Expenses
OperatingExpenses
2746364 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1603178 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2314793 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
28946 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
us-gaap Interest Expense
InterestExpense
-0 usd
us-gaap Interest Expense
InterestExpense
4134 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28946 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4134 usd
us-gaap Net Income Loss
NetIncomeLoss
-1574232 usd
us-gaap Net Income Loss
NetIncomeLoss
-2318927 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33205766 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33205766 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31650491 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31650491 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6466373 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
84717 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-428715 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6122375 usd
CY2023Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
97141 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-556044 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5663472 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
63638 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-589473 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
5137637 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2617224 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3780405 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1179286 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
591816 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-698586 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7470145 usd
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
719295 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-987529 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7201911 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
109090 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-632812 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6678189 usd
us-gaap Net Income Loss
NetIncomeLoss
-1574232 usd
us-gaap Net Income Loss
NetIncomeLoss
-2318927 usd
us-gaap Share Based Compensation
ShareBasedCompensation
245496 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1420201 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
670000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
380000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
730170 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
799913 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-443624 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-875919 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19105 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33291 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3167 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-205600 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-27607 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-35571 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-988827 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-650600 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
3780405 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3780405 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-988827 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3129805 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2002789 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330385 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1013962 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3460190 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
NEOV Conversion Of Convertible Debt And Accrued Interest Into Common Stock
ConversionOfConvertibleDebtAndAccruedInterestIntoCommonStock
0 usd
NEOV Conversion Of Convertible Debt And Accrued Interest Into Common Stock
ConversionOfConvertibleDebtAndAccruedInterestIntoCommonStock
1179286 usd
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
513962 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
1400000 usd
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1502119 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2353055 usd
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
634828 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
227516 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
2136947 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
2580571 usd
NEOV Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy1
ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy1
<p id="xdx_844_ecustom--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy1_z2D9dgDDTgaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span id="xdx_860_zSL3B8i6JK17">Allowance for Expected Credit Losses</span></i> – The Company recognizes an allowance for expected credit losses whenever a loss is expected to be incurred in the realization of a customer’s account. As of March 31, 2024 and June 30, 2023, our allowance for expected credit losses was $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20240331_zwwdRfqTcT5g">1,160,000</span> and $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20230630_zkgFih1v4CPg">490,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1160000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
490000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_zNY0kC3J2fda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span id="xdx_860_z7kKJbOF526i">Use of Estimates</span></i> – Management has made a number of estimates and assumptions in preparing these financial statements in conformity with accounting principles generally accepted in the United States of America. Actual results could differ from those estimates. As a result of the continued spread of the COVID-19 coronavirus since early 2020, economic uncertainties have arisen which could impact business operations, supply chains, energy demand, and commodity prices that are beyond our control. Overall, we have not experienced a material adverse impact to our economic performance or ability to continue our business operations as a result of COVID-19. We continue to monitor COVID-19, but do not believe it will have a material unfavorable impact to our future financial performance at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1013962 usd
CY2024Q1 NEOV Working Capital
WorkingCapital
5137637 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.02
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.02
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y3M18D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1179750 shares
CY2024Q1 NEOV Warrants Exercisable Weighted Average Exercise Price
WarrantsExercisableWeightedAverageExercisePrice
4.02
NEOV Warrants And Rights Outstanding Term Exercisable
WarrantsAndRightsOutstandingTermExercisable
P3Y3M18D
CY2024Q1 NEOV Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
245496 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1420201 usd
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-003236-index-headers.html Edgar Link pending
0001683168-24-003236-index.html Edgar Link pending
0001683168-24-003236.txt Edgar Link pending
0001683168-24-003236-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
neov-20240331.xsd Edgar Link pending
neovolta_ex3101.htm Edgar Link pending
neovolta_ex3102.htm Edgar Link pending
neovolta_ex3201.htm Edgar Link pending
neovolta_ex3202.htm Edgar Link pending
neovolta_i10q-033124.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
neov-20240331_cal.xml Edgar Link unprocessable
neov-20240331_def.xml Edgar Link unprocessable
neov-20240331_lab.xml Edgar Link unprocessable
neov-20240331_pre.xml Edgar Link unprocessable
neovolta_i10q-033124_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable